What does this research mean for the field?

Dipyridamole significantly decreases platelet adhesion, aggregation, and platelet factor 4 availability in humans, with these inhibitory effects correlating directly with blood dipyridamole levels and reducing function below normal limits at concentrations above 3.5 micromol/L. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

April 1, 1977Open Access

The effect of dipyridamole on platelet function: correlation with blood levels in man.

Key Points

Key points are not available for this paper at this time.

Abstract

1 The effect on platelet functions of dipyridamole (a pyrimido-pyrimidine compound) was compared with a control group of patients taking warfarin. 2 Adhesion, aggregation and platelet factor 4 availability showed a significant decrease in the dypyridamole group. 3 Aggregation and platelet factor 4 showed a significant correlation with blood dipyridamole level. 4 Adhesion, aggregation and platelet factor 4 were reduced below the lower limit of normal at blood dipyridamole levels above 3.5 micronmol/1.

Read Full Paperexternally

AIに質問

Bookmark

View Full Paper

Cite This Study

Rajah et al. (Fri,) studied this question.

synapsesocial.com/papers/6a162953599ca9964c8e8da7 https://doi.org/https://doi.org/10.1111/j.1365-2125.1977.tb00683.x

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AIに質問

Bookmark

View Full Paper